Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

NMPA’s response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a...
September 12, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation...
September 08, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital$125 million financing upfront with...
August 27, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...
August 11, 2025 06:00 ET | Source: Belite Bio, Inc

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected by Q4 2025 (including a three-month...
August 07, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Registered Direct Offering of $15 Million

The offering was to a single large existing institutional shareholder SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage drug...
August 06, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...
August 04, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...
July 23, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the BTIG Virtual Biotechnology Conference

SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...
July 02, 2025 03:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

- 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio,...